[1]黄秉文.中美两种2型糖尿病肾病诊断标准中疾病进展及预后因素对比[J].医学信息,2018,31(22):68-72.[doi:10.3969/j.issn.1006-1959.2018.22.019]
　HUANG Bing-wen.Comparison of Disease Progression and Prognostic Factors in Two Diagnostic Criteria for Type 2 Diabetic Nephropathy in China and the United States[J].Journal of Medical Information,2018,31(22):68-72.[doi:10.3969/j.issn.1006-1959.2018.22.019]
点击复制

中美两种2型糖尿病肾病诊断标准中疾病进展及预后因素对比()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年22期
页码:
68-72
栏目:
论著
出版日期:
2018-11-15

文章信息/Info

Title:
Comparison of Disease Progression and Prognostic Factors in Two Diagnostic Criteria for Type 2 Diabetic Nephropathy in China and the United States
文章编号:
1006-1959（2018）22-0068-05
作者:
黄秉文
(佛山市第二人民医院内分泌科，广东 佛山 528000)
Author(s):
HUANG Bing-wen
(Department of Endocrinology,the Second People's Hospital of Foshan,Foshan 528000,Guangdong,China)
关键词:
2型糖尿病肾病; 肾小球滤过率; 诊断标准
Keywords:
Type 2 diabetic nephropathy; Glomerular filtration rate; Diagnostic standard
分类号:
R587.2
DOI:
10.3969/j.issn.1006-1959.2018.22.019
文献标志码:
A
摘要:
目的 通过对美国肾脏病基金会肾脏病预后质量倡议（NKF K/DOQI）标准及中华医学会糖尿病学分会微血管并发症学组的标准所描述的2型糖尿病肾病疾病进展及预后因素进行对比，评估两种标准的临床应用价值。方法 选取2016年4月~2017年4月于佛山市第二人民医院就诊的2型糖尿病患者共280例作研究对象，其中符合NKF K/DOQI标准的2型糖尿病肾病患者70例，符合中华医学会标准者80例。记录两种标准2型糖尿病肾病患者的肾小球滤过率，两组患者接受1年回访后对上述指标进行复查，统计两种标准患者的肾功能进展性下降的比例并进行对比。使用Spearson法分析eGFR下降幅度与各可能危险因素的相关性，使用Logistic回归模型分析随访后eGFR下降与各可能危险因素的相关性。结果 中华医学会标准诊断2型糖尿病患者的糖尿病肾病患病率为：28.57%（80/280）；NKF K/DOQI标准诊断2型糖尿病患者的糖尿病肾病患病率为25.00%（70/280）；按中华医学会标准，正常白蛋白尿的2型糖尿病肾病患者占2型糖尿病肾病患者的12.50%（10/80）；两种标准下，糖尿病肾病患者出现eGFR降低≥4%/年的比例均高于非糖尿病肾病者，中华医学会标准组为：20.00% vs 9.00%（P＜0.05）；NKF K/DOQI标准组为：17.14% vs 6.67%（P＜0.05）；两种标准下糖尿病肾病与非糖尿病肾病在eGFR降低＜4%及eGFR无下降的患者比较，差异无统计学意义（P＞0.05）；Logistic回归分析中，校正年龄、血糖、病程等危险因素后，中华医学会标准下糖尿病病程≥10年、HbA1C、基线eGFR与eGFR进展性下降存在显著相关性；NKF K/DOQI标准下糖尿病病程≥10年、高血压、HbA1C、基线eGFR、糖尿病视网膜病变与eGFR进展性下降存在显著相关性。结论 两种标准诊断的糖尿病肾病患者肾功能进展性下降程度均高于非糖尿病肾病患者，预测两种标准糖尿病肾病发生肾功能进展性下降的基线预后因素相似，本研究对中华医学会标准将正常白蛋白尿但eGFR下降的临床亚型归入2型糖尿病肾病诊断范畴的建议提供了流行病学的间接证据。
Abstract:
Objective To make a comparison of progression and prognostic factors on type 2 diabetic nephropathy severally described by National Kidney Foundation of clinical practice guidelines of America(NKF K/DOQI) and the standard of microvascular complication Group of Diabetes Society of Chinese Medical Association,and to evaluate the clinical value of the two criteria.Methods 280 patients with type 2 diabetes mellitus were selected from April 2016 to April 2017 in Foshan Second People's Hospital.There were 70 patients with type 2 diabetic nephropathy who met the NKF K/DOQI standard and 80 cases met the standard of Chinese Medical Association.The glomerular filtration rate was recorded in patients with type 2 diabetic nephropathy diagnose by the two standards.The two groups of patients received a year's visit to review the above indicators,the rate of progressive decline in renal function was measured and compared between the two groups of patients with standards.Spearson method was used to analyze the correlation between the decrease of eGFR and possible risk factors.Logistic regression model was used to analyze the correlation between eGFR decline and possible risk factors after follow-up.Results The prevalence of diabetic nephropathy was 28.57%(80/280) in type 2 diabetic patients diagnosed by the standard of Chinese Medical Association.The prevalence of diabetic nephropathy in patients with type 2 diabetes diagnosed by NKF K/DOQI criteria was 25.00%(70/280);According to the Chinese Medical Association standards,normal albuminuria type 2 diabetic nephropathy patients accounted for 12.50%(10/80) of type 2 diabetic nephropathy patients.Under both standards,the proportion of patients with diabetic nephropathy who had decreased eGFR≥4%/a year was higher than that with non-diabetic nephropathy.The group of the standard of Chinese Medical Association was 20.00% vs 9.00% (P<0. 05);The NKF K/DOQI standard group was 17.14% vs 6.67%(P<0. 05).There was no significant difference (P>0. 05) between diabetic nephropathy and non-diabetic nephropathy in patients with decreased eGFR <4% and no decrease in eGFR under two standards.And in Logistic regression analysis,after adjusting for age, blood glucose, course of disease and other risk factors,there was a significant correlation between a duration of diabetes≥10 years,HbA1C, baseline eGFR and progressive decline of eGFR under the standard of Chinese Medical Association;A duration of diabetes≥10 years,Hypertension, HbA1C, baseline eGFR, diabetic retinopathy and progressive eGFR decreased significantly under the NKF K/DOQI standard.Conclusion The degree of progressive decline of renal function in patients with diabetic nephropathy diagnosed by both criteria was higher than that in patients with non-diabetic nephropathy under both of the standards,and the baseline prognostic factors for predicting progressive decline of renal function in two standard diabetic nephropathy were similar.This study provides epidemiological circumstantial evidence for the recommendation of the Chinese Medical Association to classify the clinical subtypes of normal albuminuria but decreased eGFR into the diagnostic category of type 2 diabetic nephropathy.

参考文献/References:


[1]Zhuo L,Zou G,Li W,et al.Prevalence of diabetic nephropathy complicating non-diabetic renal disease among Chinese patient with type 2 diabetes mellitus[J].Eur J Med Res,2013,18(1):652-667.
[2]Riella MC.Kidney Disease:Improving Global Outcomes(KDIGO)CKD Work Group.KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease[J].Kidney International Supplements,2013,3(1):1-150.
[3]中华医学会糖尿病学分会微血管并发症学组.糖尿病肾病防治专家共识(2014年版)[J].中华糖尿病杂志,2014,6(11):792-801.
[4]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中华糖尿病杂志,2014,12(7): 1851-1875.
[5]李青,潘洁敏,包玉倩,等.2型糖尿病住院患者糖尿病肾脏疾病的发生率及危险因素分析[J].中国中西医结合肾病杂志,2014,7(10):891-894.
[6]Lu B,Gong W,Yang L,et al.An evaluation of the diabetic kidney disease definition in chinese patients diagnosed with type 2 diabetes mellitus[J].Eur J Med Res,2015,5(5):271-275.
[7]许山荣,钟一红,陈波,等.上海市效区2型糖尿病患者肾脏疾病及其危险因素研究[J].中华内科杂志， 2012,51(1):18-23.
[8]Tuttle KR,Bakris GL,Bilous RW,et al.Diabetic Kidney Disease:A Report From an ADA Consensus Conference[J].J Int Med Res,2014,64(5):1483-1489.
[9]李文歌,李征,谌贻璞,等.上海地区成人慢性肾脏病流行病学调查[J].中华肾脏病杂志, 2013,12(9):18 -25.
[10]胡仁明,龚伟,傅一飞,等.住院2型糖尿病合并正常白蛋白尿的慢性肾脏病患者临床特征及危险因素分析[J].中华糖尿病杂志,2018,4(15):62-69.
[11]Tervaert TW,Mooyaart AL,Amann K,Cohen AH,et al.Pathologic classification of diabetic nephropathy[J].Am J Kidney Dis,2012,4(4):850-856.

相似文献/References:

[1]朱津津.Hcy、BNP检测在2型糖尿病肾病早期诊断中的价值分析[J].医学信息,2018,31(03):163.[doi:10.3969/j.issn.1006-1959.2018.03.060]
　ZHU Jin-jin.The Value of Hcy and BNP in the Early Diagnosis of Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2018,31(22):163.[doi:10.3969/j.issn.1006-1959.2018.03.060]
[2]张国锐,贾 林,赵 丹,等.老年维持血液透析患者恶性肿瘤发病的相关因素分析[J].医学信息,2022,35(10):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
　ZHANG Guo-rui,JIA Lin,ZHAO Dan,et al.Analysis of Related Factors of Malignant Tumor in Elderly Maintenance Hemodialysis Patients[J].Journal of Medical Information,2022,35(22):113.[doi:10.3969/j.issn.1006-1959.2022.10.027]
[3]高 彬,孙 娜,常文秀.慢性肾脏病患者血钾异常相关因素分析[J].医学信息,2019,32(22):91.[doi:10.3969/j.issn.1006-1959.2019.22.027]
　GAO Bin,SUN Na,CHANG Wen-xiu.Analysis of Related Factors of Serum Potassium Abnormality in Patients with Chronic Kidney Disease[J].Journal of Medical Information,2019,32(22):91.[doi:10.3969/j.issn.1006-1959.2019.22.027]
[4]伊学军,翟建新.胱抑素C检测及其在肾脏相关疾病中的应用[J].医学信息,2020,33(04):55.[doi:10.3969/j.issn.1006-1959.2020.04.017]
　YI Xue-jun,ZHAI Jian-xin.Cystatin C Detection and its Application in Kidney-related Diseases[J].Journal of Medical Information,2020,33(22):55.[doi:10.3969/j.issn.1006-1959.2020.04.017]
[5]赵海莲.血尿酸水平与2型糖尿病肾病患者肾脏损害的相关性分析[J].医学信息,2020,33(06):93.[doi:10.3969/j.issn.1006-1959.2020.06.027]
　ZHAO Hai-lian.Correlation Between Serum Uric Acid Level and Renal Damage in Patients with Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2020,33(22):93.[doi:10.3969/j.issn.1006-1959.2020.06.027]
[6]段宗宝,肖三法,罗惠群.环磷酰胺联合氢氯噻嗪治疗2型糖尿病肾病的临床研究[J].医学信息,2021,34(23):159.[doi:10.3969/j.issn.1006-1959.2021.23.048]
　DUAN Zong-bao,XIAO San-fa,LUO Hui-qun.Clinical Study of Cyclophosphamide Combined with Hydrochlorothiazide in the Treatment of Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2021,34(22):159.[doi:10.3969/j.issn.1006-1959.2021.23.048]
[7]左俊荣.特发性膜性肾病的诊断及治疗研究[J].医学信息,2021,34(11):54.[doi:10.3969/j.issn.1006-1959.2021.11.016]
　ZUO Jun-rong.Research on the Diagnosis and Treatment of Idiopathic Membranous Nephropathy[J].Journal of Medical Information,2021,34(22):54.[doi:10.3969/j.issn.1006-1959.2021.11.016]
[8]陈 甜,付朝霞.中性粒细胞明胶酶相关脂质运载蛋白对早期糖尿病肾病的诊断价值[J].医学信息,2023,36(23):95.[doi:10.3969/j.issn.1006-1959.2023.23.024]
　CHEN Tian,FU Zhao-xia.Diagnostic Value of Neutrophil Gelatinase-associated Lipocalin in Early-stage Diabetic Nephropathy[J].Journal of Medical Information,2023,36(22):95.[doi:10.3969/j.issn.1006-1959.2023.23.024]
[9]付彩雯,吴 艳.FGF23/Klotho在2型糖尿病肾病和骨质疏松共病中的研究现状[J].医学信息,2024,37(03):176.[doi:10.3969/j.issn.1006-1959.2024.03.037]
　FU Cai-wen,WU Yan.Research Status of FGF23/Klotho in the co-morbidities of Type 2 Diabetic Nephropathy and Osteoporosis[J].Journal of Medical Information,2024,37(22):176.[doi:10.3969/j.issn.1006-1959.2024.03.037]
[10]阎 丽,宋 迎.甲状腺激素与不同阶段2型糖尿病肾病的相关性研究[J].医学信息,2022,35(19):155.[doi:10.3969/j.issn.1006-1959.2022.19.045]
　YAN Li,SONG Ying.Study on the Correlation Between Thyroid Hormone and Different Stages of Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2022,35(22):155.[doi:10.3969/j.issn.1006-1959.2022.19.045]

更新日期/Last Update: 2018-12-03